Director Michael A. Kelly resigns; Board adopts 2023 Inducement Plan reserving 500,000 shares

HOOKIPA Pharma Inc.

Director Michael A. Kelly resigned effective April 7, 2023, not due to any disagreement with the Company.
Terry Coelho appointed Chair of Audit Committee to fill vacancy; deemed audit committee financial expert.
Board approved 2023 Inducement Plan reserving 500,000 shares of common stock for new employee inducement grants.
Awards under the plan limited to employees commencing employment, per Nasdaq Rule 5635(c)(4).

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Michael A. Kelly

Director

HOOK · HOOKIPA Pharma Inc.

Effective: 2023-04-07
Filed: April 13, 2023, 7:59 PM ET

On April 7, 2023, Michael A. Kelly, a member of the Board, notified the Company of his resignation from the Board, including the Audit Committee of the Board (the “Audit Committee”), on which he serves as the Chair and a member and the Compensation Committee of the Board on which he serves as a member, effective April 7, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael A. Kelly resigned as Director at HOOKIPA Pharma Inc..

Action: resigned
Role: Director

Exact text from the filing

On April 7, 2023, Michael A. Kelly, a member of the Board, notified the Company of his resignation from the Board, including the Audit Committee of the Board (the “Audit Committee”), on which he serves as the Chair and a member and the Compensation Committee of the Board on which he serves as a member, effective April 7, 2023.

View on SEC.gov

HOOKIPA Pharma Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-045006

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.